Literature DB >> 12684147

A comparative randomized study of three different IUDs in nulliparous Mexican women.

J B Otero-Flores1, F J Guerrero-Carreño, L A Vázquez-Estrada.   

Abstract

With the aim to evaluate the clinical performance of intrauterine devices (IUDs) especially designed for nulliparous women (TCu 380 Nul and ML Cu 375 sl), a prospective randomized, single-blind study comparing them with standard TCu 380 A, was carried out. We included 1170 healthy nulliparous women randomly allocated to receive any of the three types of IUDs and conducted follow-up for 1 year of use. Continuation and termination rates were evaluated by gross cumulative life table analysis and compared by the log-rank test. Continuation rates (95% confidence interval) at the end of the study for TCu 380 A, TCu 380 Nul and ML Cu 375 sl were 29.5% (+/-12.9), 85.9% (+/-5.3) and 85.4% (+/-5.8), respectively (p < 0.001). There were six pregnancies during the first 3 months of use, for a failure rate of 1% (+/-0.6) in the TCu 380 A group, 0.5% (+/-0.3) in TCu 380 Nul, and no pregnancy in ML Cu 375 sl (p < 0.05). Especially designed IUDs for nulliparous women had a better clinical profile compared with the standard IUD. This may improve the use of IUD in this population.

Entities:  

Mesh:

Year:  2003        PMID: 12684147     DOI: 10.1016/s0010-7824(02)00519-x

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  9 in total

1.  Barriers to contraceptive use in product labeling and practice guidelines.

Authors:  Daniel Grossman; Charlotte Ellertson; Katrina Abuabara; Kelly Blanchard; Francisco T Rivas
Journal:  Am J Public Health       Date:  2006-01-31       Impact factor: 9.308

2.  Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trial.

Authors:  David Hubacher; Courtney A Schreiber; David K Turok; Jeffrey T Jensen; Mitchell D Creinin; Kavita Nanda; Katharine O'Connell White; Ila Dayananda; Stephanie B Teal; Pai-Lien Chen; Beatrice A Chen; Alisa B Goldberg; Jennifer L Kerns; Clint Dart; Anita L Nelson; Michael A Thomas; David F Archer; Jill E Brown; Paula M Castaño; Anne E Burke; Bliss Kaneshiro; Diana L Blithe
Journal:  EClinicalMedicine       Date:  2022-07-16

3.  Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device.

Authors:  Bliss Kaneshiro; Tod Aeby
Journal:  Int J Womens Health       Date:  2010-08-09

Review 4.  Copper containing intra-uterine devices versus depot progestogens for contraception.

Authors:  G Justus Hofmeyr; Mandisa Singata; Theresa A Lawrie
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

5.  Safety, efficacy and patient acceptability of the contraceptive and non-contraceptive uses of the LNG-IUS.

Authors:  Paula H Bednarek; Jeffrey T Jensen
Journal:  Int J Womens Health       Date:  2010-08-09

6.  Use of frameless intrauterine devices and systems in young nulliparous and adolescent women: results of a multicenter study.

Authors:  Dirk Wildemeersch; Sohela Jandi; Ansgar Pett; Kilian Nolte; Thomas Hasskamp; Marc Vrijens
Journal:  Int J Womens Health       Date:  2014-08-06

7.  Intrauterine contraception in nulliparous women: a prospective survey.

Authors:  Alexandra M Hall; Beth A Kutler
Journal:  J Fam Plann Reprod Health Care       Date:  2015-04-08

8.  Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis.

Authors:  Peihai Zhang; Kun Song; Li Li; Kazunori Yukuwa; Beihua Kong
Journal:  Med Princ Pract       Date:  2013-06-19       Impact factor: 1.927

9.  Systematic review of copper intrauterine contraception continuation in young nulliparous women based on intrauterine device type.

Authors:  Hannat Akintomide; Alison James; Malcolm Moffat; Pam Barnes; Judith Rankin
Journal:  BMJ Open       Date:  2022-10-03       Impact factor: 3.006

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.